Kuno, 9,565 patient famotidine late treatment PSM study: no change in mortality [p=0.97] https://c19p.org/kuno2
copied to clipboard
The association between famotidine and in‐hospital mortality of patients with COVID‐19
et al., Journal of Medical Virology, doi:10.1002/jmv.27375
PSM retrospective 9,565 COVID-19 hospitalized patients in the USA, 1,593 receiving famotidine, showing no significant difference in mortality.
|
risk of death, no change, OR 1.00, p = 0.97, treatment 1,593, control 7,972, RR approximated with OR.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Kuno et al., 10/11/2021, retrospective, propensity score matching, USA, North America, peer-reviewed, 4 authors, study period 1 March, 2020 - 30 March, 2021.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.